key: cord-0731168-owv6quli
authors: Louchet, Margaux; Sibiude, Jeanne; Peytavin, Gilles; Picone, Olivier; Tréluyer, Jean-Marc; Mandelbrot, Laurent
title: Placental transfer and safety in pregnancy of medications under investigation to treat COVID-19
date: 2020-06-22
journal: Am J Obstet Gynecol MFM
DOI: 10.1016/j.ajogmf.2020.100159
sha: 6781845d9c6d05c033a2a29380fa0a28952ba7e2
doc_id: 731168
cord_uid: owv6quli

Abstract Background Treatment of COVID-19 is mostly symptomatic, but a wide range of medications are under investigation against SARS-CoV-2. Although pregnant women are excluded from clinical trials, they will inevitably receive therapies whenever they appear effective in non-pregnant patients and even under compassionate use. Method We conducted a review of the literature on placental transfer and pregnancy safety data of drugs under current investigation for COVID-19. Results Regarding remdesivir, there are no data in pregnant women. Several other candidates already have safety data in pregnant women, since they are repurposed drugs already used for their established indications. They may thus be used in pregnancy, although their safety in the context of COVID-19 may differ from conventional use. These include the HIV protease inhibitors such as lopinavir/ritonavir which have low placental transfer; interferon which does not cross the placental barrier, and (hydroxy) chloroquine, which have high placental transfer. There are also pregnancy safety and placental transfer data for colchicine, steroids, oseltamivir and azithromycin, as well as some monoclonals. However, some drugs are strictly prohibited in pregnancy due to known teratogenicity (thalidomide) or fetal toxicities (renin-angiotensin system blockers). Other candidates including tocilizumab and other IL-6 inhibitors, umifenovir and favipiravir have insufficient data on pregnancy outcomes. Conclusion In life-threatening cases of COVID-19, the potential risks of therapy to the fetus may be more than offset by the benefit of curing the mother. While preclinical and placental transfer studies are required for a number of potential anti-SARS CoV2 drugs, several medications can already be used in pregnant women.

The current COVID-19 pandemic is a global health emergency which affects all populations, 54 including pregnant women (1, 2) . COVID-19 disease can result in maternal morbidity and 55 against SARS-CoV-2, blocking infection (45) and virus replication with a IC50 of 9.12 (22) . 142

Chloroquine is under investigation in several clinical studies for the treatment of COVID- 19 143 (46) . including miscarriages, no increased risk has been reported, including (57) . In humans, stud-155 ies have not shown any teratogenic or fetotoxic effect in the event following in utero expo-156 sure ; in particular no risk of ocular damage in newborns in a meta-analysis including 588 157 infants (58) . 158

Hydroxychloroquine is also an anti-malarial derived from amino-4-quinoline with an anti-159 inflammatory action. It has a molecular mass of 335.9g/mol, is lipophilic and has 45% protein 160

binding. It has demonstrated antiviral activity against SARS-CoV-2 in small in vitro studies 161 (59, 60) and some studies have reported that hydroxychloroquine reduces viral excretion 162 (29, 61) . "Compassionate use has been authorized in COVID-19 patients (66) , and a large 163 number of observational studies have been performed worldwide been published with con-164 flicting conclusions on its efficacy and safety on COVID-19 (62) (63) (64) (65) (66) (67) (68) (69) (70) (71) , and randomized clinical 165 trials are currently underway (53 studies are available in clincaltrial.gov website with "includ-166

ing" and randomized statement criteria." (NCT04329923, NCT 04307693, 167

ChiCTR2000029559, ChiCTR2000029898-99, ChiCTR2000029992). 168

Hydroxychloroquine is recommended for patients with rheumatoid arthritis and lupus. It 169 obtained marketing authorization in these indications in 1997 (72) . Hydroxychloroquine tox -170 icities are retinopathy in case of long-term treatment at high doses (prevalence from 2 to 171 8%) (73, 74) and heart conduction disorders (75) , more rarely ventricular tachyarrhythmia or 172 QT prolongation . 173 Hydroxychloroquine has been shown to be safe for use in pregnant women at doses of 200 174 mg once or twice a day. It crosses the placenta by passive diffusion with a strong correlation 175 between maternal and fetal concentrations and a fetal/maternal concentrations ratio of 176

1.04 (range 0.51 to 1.82 ) (76) . Pregnancy outcomes in the event of exposure are similar to 177 those of untreated women with the same conditions (number of miscarriages and rate of 178 malformation in particular) (77) (78) (79) . There has been no reported increase in visual disturb -179 ances in newborns of exposed women (80) . 180 181

The fixed combination lopinavir/ritonavir has been widely used for the treatment of adults 183 living with HIV. Lopinavir has a molecular mass of 1349.7g/mol, is practically insoluble in 184 water and has a protein binding rate of 98-99%. Lopinavir is a protease inhibitor prescribed 185 in combination with ritonavir, an inhibitor of the isoform CYP3A4 of cytochrome p450 which 186 is used as a booster to obtain therapeutic plasma concentrations. It has in vitro and in vivo 187 efficiency against SARS-CoV-1 and MERS infections (81, 82) . It is considered as an option for 188 COVID-19 treatment in several trials, although the first randomized, open-label, controlled 189 study to be published reported no significant benefit of lopinavir/ritonavir (83) . 190

The tolerability of lopinavir/ritonavir is poorer than for other HIV protease inhibitors, espe-191 cially regarding digestive disorders and lipid abnormalities (84) . In the randomized controlled 192 trial from China in adults with severe Covid-19 infection (83), treatment (400mg/100mg 193 twice a day) had to be stopped early for 13.8% (n=13) of patients because of adverse events 194 (primarily gastrointestinal adverse events). This incidence of severe adverse events was 195 higher than reported in HIV infection at the same dose. Lopinavir/ritonavir exposure in -196 creases plasma concentrations of CYP 3A4 metabolized drug taken concurrently . 197 In pregnant women living with HIV, lopinavir/ritonavir was for several years the most widely-198 used antiretroviral therapy, with a nucleoside reverse transcriptase backbone (85) , as well as 199 in monotherapy (at 400mg/100mg, twice daily) (86) . During pregnancy, the clearance of the 200 free form of lopinavir / ritonavir is not changed and experts do not recommend increasing 201 the dosage of the drug (generally 400mg of lopinavir/100 mg of ritonavir b.i.d.) (87) . Lop-202 inavir/ritonavir crosses the placenta but poorly. Fetal transfer rates with perfused cotyledon 203 model are around 20 to 25% (88) and level in cord blood is undetectable in studies with 204 cord-to-mother ratios (89, 90) . This is due to strong protein binding for protease inhibitors 205 and to the efflux mechanism of the placental membrane transporters and in particular to P-206 glycoprotein (91) (92) (93) . 207

Pregnancy outcomes were reported to be similar to control women living with HIV (19, 20) . 208

There was no increase in the rate of congenital malformations after first-trimester exposure. 209 A large randomized trial has shown a higher rate of preterm births in the groups treated with 210 lopinavir/ritonavir-based ART as compared to monotherapy of zidovudine (94) . This has al-211 ready been described in a randomized trial comparing lopinavir/ritonavir-based ART to a 212 combination of 3 nucleoside reverse transcriptase inhibitors (95) . 213

In addition, several cases of lopinavir/ritonavir toxicity have been described in treated pre-214 term infants, in particular signs suggesting adrenal insufficiency with hyponatremia and hy-215 perkalemia (96) . These undesirable effects led in 2011 to an alert by the FDA and to the con-216 traindicated of this association in premature babies (84) . 217 218

Remdesivir (GS-5734) is a prodrug of a nucleoside analog antiviral. It has a molecular mass of 220 602.9 g/mol with a protein binding rate of 85-92 % in animal studies. It is metabolized by the 221 liver and has a renal and biliary excretion. Its water solubility is not yet available on the Pub-222

Chem website. It is metabolized into its active form GS-441524. It competes with ATP and 223

inhibits the viral RNA-polymerase (97) . Remdesivir was initially developed against Ebola vi-224 rus, with efficacy in a clinical phase III trial study (98) . It has also been studied to treat MERS-225

CoV and SARS-CoV-1 coronavirus infections (99) . Its efficacy against SARS-CoV-2 has been 226 proven in vitro (45,100) with IC50 of 11.41 o 6.25μM associated with emetine (21, 22) and in 227 vivo in animals (101) . Its mechanisms of action (shortening of the DNA chain or modification 228 of excision activity) remain to be explained in detail (99, 102) . A number of clinical trials are 229 underway to determine the efficacy and safety of remdesivir to treat COVID-19 230 (NCT04252664, NCT04257656, NCT04280705, NCT04292730, NCT04292899). "Two double-231 blinded randomized clinical trials have been published using an intravenous loading dose of 232 200 mg followed by 100 mg daily for 10 days (103, 104) . Both showed a reduction of time to 233 clinical improvement (103) . Similar results have been reported in compassionate use for se-234 vere patients (105) ." 235

To date, tolerance data in humans are sparse. There is a risk of renal dysfunction (106-108) 236 and elevated liver enzymes, and a possible effect on mitochondrial functions (106), as well 237 as a case of cardiac arrest in a clinical trial on Ebola infection (98) . Thus, investigators rec-238 ommended biological monitoring of liver and kidney functions. "Clinical trials in COVID-19 239 disease also report adverse effects with an incidence ranging from 21 to 66 %" (103) (104) (105) . 240

Regarding pregnant women, 6 women who were treated with remdesivir in a clinical study 241 on Ebola disease had positive pregnancy tests (98) , but these cases were not described. We 242 found no study addressing the safety of remdesivir in pregnant women, nor its placental 243 transfer. Considering its small molecular weight and its high protein-binding rate, we may 244 expect that remdesivir crosses the placenta. Oseltamivir is widely recommended to treat influenza in children or adults considered at risk 251 of severe manifestations, including pregnant women. According to the ex vivo human pla-252 cental perfusion, oseltamivir and its metabolite oseltamivir carboxylate, cross poorly the 253 placenta with transfer rates of 12.39 and 10.17% respectively (111) . Retrospective study 254 with large population do not provide evidence of risk of any major congenital malformation 255 nor in heart defect (112) . No evidence of increased risk of preterm birth nor small for gesta-256 tional age infants was reported in another prospective study (112, 113) . We did not find any 257 information about pregnancy and zanamivir, another neuraminidase inhibitor. 258

Favipiravir is an antiviral drug approved in Japan and China for influenza which inhibits the 259 RNA polymerase enzyme (114, 115) . It has shown efficacy against Ebola virus in animals and 260

humans (116, 117) . A potential synergistic benefit of favipiravir associated with oseltamivir 261 has been described in influenza (118) (119) . Favipiravir is under investigation for treating 262 SARS-CoV-2 in several clinical trials (NCT04310228, NCT04358549). We found no information 263 about the use of favipiravir in pregnant women but caution is needed because of a warning 264 by the Japanese drug agency on a teratogenic risk in preclinical animal studies (114, 120) . 265

The combination of alpha-interferon and ribavirin (an antiviral mainly used to treat hepatitis 266 C) is also under investigation in COVID-19, even though it has not been proven to reduce 267 mortality for the treatment of MERS-CoV (121, 122) . In pregnant women, ribavirin is usually 268 mations. However, the use of boosted protease inhibitors has been associated with an in-276 creased risk of preterm delivery, although it is not clear whether the impact is related to any 277 specific drug or to other confounding factors (124) . Nelfinavir is a selective inhibitor of HIV 278 protease which has been reported to inhibit replication of SARS-CoV replication in vitro 279 (125) . The placental transfer of nelfinavir is low (90) . There is no increase in the risk of con-280 genital malformations. 281

Arbidol hydrochloride (umifenovir) is an immunomodulator and a broad-spectrum antiviral 282 drug. Arbidol is able to block viral fusion against influenza viruses and has been reported to 283 have antiviral in vitro activity against SARS-CoV (126). It has been reported to increase the 284 effect of lopinavir/ritonavir treatment on SARS-CoV-2 excretion at 7 and 14 days in a retro-285 spective cohort study (n=33 patients) (127), but clinical outcomes have not yet been as-286 sessed (128) . Arbidol is under investigation in a randomized controlled phase 4 study, com-287 pared to lopinavir/ritonavir, and to oseltamivir (NCT04255017). A study reports its use, in 288 association with others antiviral drugs, in 7 pregnant women with SARS-CoV-2 infection 289 (129) . We found no information on safety of umifenovir in pregnancy. sheep with limited fetal exposure (130) . Data on safety for pregnant women and neonates 297 are sparse and a recent meta-analysis has concluded to insufficient evidence for its safety 298 profile in pregnancy (131) . Nitazoxanide is another antiparasitic drug under consideration 299 (NCT04343989) for which we found no specific data on specific use in pregnant women. 300

The FDA-approved antihelminthic drug niclosamide has shown in vitro antiviral efficacy 301 against SARS-Cov-2 (22). As mentioned above, the amebicide emetine inhibit SARS-CoV-2 302

replication (21, 22) and has been studied in association with remdesivir." 303 304 Interferon 305

Interferon beta and lambda are both studied as COVID-19 therapy but most information 306 concerns interferon beta. Interferon beta is a cytokine with antiviral, anti-proliferative and 307 immunomodulatory activities. It is commonly used to treat multiple sclerosis. It is a glyco-308 protein that works after it has attached to the cell membrane by triggering a cascade of in-309 tracellular signaling with in particular the induction of enzymes which could inhibit viral rep-310 lication in infected cells. Interferon beta has been proposed as immune-modulatory treat-311 ment to control the massive inflammation resulting in lung injury in SARS-CoV-2 infection. 312

There is a long experience of safety and tolerability of interferon in non-pregnant adults and 313 the most frequently reported adverse events are injection site reactions, asthenia, flu-like 314 symptoms, headache and lymphopenia (132) . 315

Pregnancy outcomes in women treated with interferon beta have been documented in pro-316 spective and retrospective pharmacovigilance studies on 1348 and 99948 pregnant women, 317 respectively (133) (134) (135) . The prescribed subcutaneous doses ranged from 30 μg/0.5mL/week 318 to 30 μg/0.5mL three times a week. These studies did not find an increased risk of miscar-319 riage or congenital malformation associated with treatment with beta interferon. Other per-320 inatal outcomes were not described. 321

We did not find any study on the transplacental passage of interferon beta. However, inter-322 ferons have high molecular weights and it has been shown that interferon alpha does not 323 cross the placenta in humans, according to data in the ex vivo cotyledon perfusion model 324 (136, 137) as well as neonatal cord blood samples (138) . By analogy, we can assume that be-325 ta interferon does not cross the placental barrier. 326 327

Transfusion of immunoglobulins from patients who have recovered from the disease is a 329 passive immunotherapy. Convalescent plasma transfusion has been previously described as 330 a therapeutic option in management of Ebola and previous coronavirus infections (139, 140) . 331

It was not associated with a significant improvement in survival in Ebola patients (141) safety (150) . Even fewer data are available regarding sarilumab/siltuximab. As other immu-371 noglobulin G antibodies of the IgG 1 subclass, they cross the placenta. Immune response may 372 be impaired in infants exposed in utero. A registry has been established to monitor out-373 comes following exposure to anti-IL6 monoclonals during pregnancy. "Other anti-interleukin 374 inhibitors (anti-IL1) also under study are canakinumab (NCT 04362813) and anakinra (NCT 375 04362813). A retrospective study in 31 exposed-women has reported global sparse reassur-376 ing data with no neonatal infection but renal agenesis in one fetus after anakinra exposition 377 (151) ." 378

The sphingosine-1-phosphate receptor regulator fingolimod (FTY720) is an immune modula-379 tor which prevents lymphocytes contribution to autoimmune reaction. It also has been pro-380 posed in COVID-19 therapy (NCT 04280588). Fingolimod has been widely used in severe mul-381 tiple sclerosis. It is generally well-tolerated and has a long term safety profile (including in-382 fection or malignancy rates) (152,153) but serious cardiac adverse effects have been report-383 ed in patients at risk of heart failure. Data on the safety in pregnant women do not show any 384 increase in major malformation rates among live births in comparison with the general 385 population and the multiple-sclerosis population (n=91 pregnancies and 75 live births) (154) . 386

We found no data on placental transfer of fingolimod. 387

Baricitinib, an anti-JAK and anti-AAK1 inhibitor was found capable to reduce or interrupt the 388 passage of the virus into target cells (endocytosis into pulmonary cell), and to inhibit the 389 JAK1-and JAK2-mediated cytokine release, constituting the rationale to perform a trial on 390 patients with mild to moderate COVID-19 (2, 155) . The drug was licensed for the treatment 391 of rheumatoid arthritis at the daily dose of 4 mg/orally, with excellent results in terms of 392 clinical response and a good safety profile (155) . Since baricitinib does not interact with anti-393 virals due to its prevalent renal elimination, it may be used in combination with antiviral 394 therapy. As biologic and small molecule, baricitinib is contraindicated in pregnancy awaiting 395 larger studies to assess its safety (156) (157) . Another anti-JAK molecules is also tested in 396 current studies, ruxolitinib (NCT04377620, NCT04334044, NCT04334044). 397

Infliximab is also under consideration for severe covid-19 pneumoniae (NCT04333420). 398

There are data from retrospective cohorts on the safety of infliximab in pregnant women 399 treated for Crohn's disease (158) . It crosses the placenta in the second and third trimester 400 and has been detected in newborn samples six months after delivery (159, 160) . 401 "Leflunomide is an immune suppressor used in rheumatoid arthritis which is also under 402 study for COVID-19 (NCT 04361214). It is teratogenic in an animal model and thus is to be 403 avoided if possible, although a small retrospective study (164) reported no association with 404 major congenital malformation after 5 cases of first trimester exposure, nor adverse preg-405 nancy outcomes after 15 second and third trimester exposures. We found no data on pla-406 cental transfer of leflunomide. 407

Additional immune therapies under study to treat the cytokine storm in COVID-19 include 408 lenzilumab, a humanized monoclonal antibody that blocks the granulocyte-macrophage 409 colony stimulating factor (GM-CSF) (NCT 04351152) and the human IgG1 monoclonal anti-410 body gimsilumab (NCT 04351243). 411

Colchicine is a powerful anti-inflammatory drug. It is under study in a simple, pragmatic ran-412 domized controlled trial for its immunomodulatory and anti-inflammatory effects, which 413 may reduce the cytokine storm and inflammatory cascade activation in severe forms of 414 COVID-19 (NCT 04328480, NCT04326790). To date, it has not been proved to be effective as 415 treatment or as prevention of COVID-19 disease (161) (162) (163) .Colchicine has been approved for 416 the treatment of various inflammatory diseases such as gout, Familial Mediterranean Fever, 417

Bechet disease and some dermatologic indications (chronic urticaria, cutaneous vasculitis 418 and psoriasis). Regarding pregnant women, colchicine is not contra indicated during preg-419 nancy (150) . Colchicine crosses the placenta (164) . A meta-analysis shows no increase inci-420 dence of miscarriage or major fetal malformations in exposed women compared to non- 

patients (NCT04318418). Another angiotensin receptor blocker telmisartan is also being 446 studied (NCT 04355936).In pregnancy, drugs that block the renin-angiotensin system can 447 damage the fetal kidneys, leading to renal failure with oligohydramnios, deformations and 448 lung hypoplasia (174, 175) . These drugs modifying the renin-angiotensin cascade could also 449 impact placental functions leading to growth retardation (176) . and visual disturbance (188) . It crosses the placenta at a high rate in ex vivo model (189) and 457 it is thus considered in antenatal care to prevent pulmonary hypertension in case of congeni-458 tal diaphragmatic hernia (190) . Sildenafil has also been studied for the prevention of fetal 459 growth restriction in case of maternal vascular disease such as pre-eclampsia and a meta-460 analysis has shown a significant increase in fetal weight at birth (191) . No increases of neo-461 natal death or congenital anomalies have been described in another meta-analysis (188) . 462

However, the STRIDER group (Sildenafil TheRapy In Dismal prognosis Early-onset intrauterine 463 growth Restriction) which was gathered in 2011 to explore effects of sildenafil in fetal 464 growth restriction recommended against the prescription of sildenafil (192, 193) . 465

cancer in pregnancy with no maternal and fetal adverse effects (177) but it is still recom-467 mend to avoid its use (178) . It has also been used during pregnancy to treat intravitreal 468 hemorrhage with local injection (179, 180) with neither no pregnancy-related complications. 469

We found no information on the placental transfer of bevacizumab. 470 471

Thalidomide is under consideration for COVID-19 (NCT04273529 and NCT04273581), but it is 473 definitively contraindicated in pregnancy because of its proven teratogenicity (181, 182) . 474

There is no information on pregnancy use, but in view of its high molecular mass (1110 476 g/mol), we may expect that it would not cross the placenta. 477

The topoisomerase II blocker etoposide, which is proposed for a clinical study in COVID-19 478 (NCT 04356690) has been reported in few case reports to treat gestational trophoblastic 479 disease or malignant teratomas (183) (184) (185) . Data on exposure during completed pregnancy 480 are sparse (186) and evidence of adverse effect is difficult to conclude because women re-481 ceived combinations of drugs. We found no data on placental transfer of etoposide. 482

A large variety of other drugs are also currently under consideration against SARS-CoV-2. 484

Dapagliflozin is an antidiabetic medication of the sodium-glucose co-transporter 2 (SGLT2) 485 inhibitor class which is under consideration to treat COVID-19 respiratory failure, sepsis and 486 multi-organ failure in a clinical trial (NCT 04350593). We found no specific data on its use 487 during pregnancy. safety data for use of colchicine, steroids, oseltamivir and azithromycin, as well as to some 499 extent monoclonals such as Infliximab and possibly tocilizumab. Some drugs are strictly pro-500 hibited in pregnancy due to known teratogenicity (thalidomide) or fetal toxicities (renin-501 angiotensin system blockers). Other candidates have insufficient pregnancy data, including 502 IL-6 inhibitors, umifenovir, and favipiravir. Importantly, remdesivir remains an investigational 503 drug with restricted use in the absence of preclinical data concerning pregnancy in view of 504 its toxicity profile (hypotension during injection, renal and liver dysfunction). The range of 505 medications under consideration to treat COVID-19 is rapidly evolving. 506

An unusual aspect of clinical trials in COVID-19 is the fact that most of the drugs under inves-507 tigation are repurposed and thus are already used in pregnant women for their established 508

indications. Because pregnant women are usually excluded from clinical trials, such pregnan-509 cy follow-up was obtained from off-label use. While some follow-up is obtained from struc-510 tured cohort studies, most studies are from retrospective registers with limited endpoints 511 and delayed and disparate collection of clinical data. Importantly, the doses used may differ 512 and the diseases treated differ widely, so that drug toxicities may be quite different. This is 513 of particular concern in patients with severe (multi-)organ failure. 514

The use of medications in pregnancy must take into account a number of important issues. 515

First, there is potential for increased toxicities to the patient herself, pharmacokinetic and 516 pharmacodynamic differences with non-pregnant individuals. Physiological changes include 517 increased volume of distribution, lower albumin concentrations and hormone-induced sus-518 ceptibility to hepatic toxicities (187) . Also, there may be an impact on placental functions 519 and potential adverse pregnancy outcomes, such as abortion, fetal growth restriction or pre-520 term delivery. Most important are the potential risks for the fetus, including teratogenicity, 521 fetal toxicities and long-term impact on the child's health. 522

Clinical trials usually exclude pregnant women and newborns even when benefits are ex-523 pected for this population type. This precautionary principle has been denounced as unjust 524 (188) . Pregnant women, according to the principle of autonomy, should be able to take re-525 sponsibility and provide consent for participation in clinical trials (189) ; even for drugs with 526 potential teratogenic risk (190) . Mostly excluding pregnant women from clinical trials pre-527 vents us from obtaining reliable safety data from the use of drugs during pregnancy. This 528 makes it very difficult to take care of pregnant patients with the prescription of drugs with-529 out proof of efficacy or tolerance established during pregnancy. It thus appears that the 530 benefits of including pregnant patients in therapeutic trials would outweigh the risks (191) . 531

Knowledge about placental transfer should be available early enough in the process of drug 532 evaluation in order to be able to move on to use in pregnant women without needless de-533 lays. Most medications cross the placenta, but the amount of placental transfer differs. Pas-534 sive diffusion is the major mechanism of transplacental transfer and depends on pharmaco-535 kinetic parameters including small molecular weight, high water solubility, polarity, and im-536 portant protein-binding rate (>90%). The other important mechanism is active transport 537 which depends on import or export protein-transporters. Three types of studies have been 538 developed to obtain information on the fetal drug exposure. Placental transfer may be esti-539 mated by the concentration ratios between the umbilical cord blood and maternal blood at 540 birth. But these studies are based on small numbers of patients. Preclinical placental transfer 541 studies are performed either in animals but those placentas differ from the human hemo-542 chorial placenta, or from experimental models (192, 193) , including the ex vivo human coty-543 ledon perfusion model (2, 3, 4) . Physiologically-based pharmacokinetic models (PBPK) have 544 also been developed to predict the fetal exposure to drugs (196) 545

Since the available evidence suggests that there is little risk of vertical transmission of SARS-546

CoV-2, there is no need for antiviral therapies to cross the placenta. Nor is there any benefit 547 to be expected from fetal exposure to immunomodulatory therapies. Thus, the optimal ap-548 proaches to treating pregnant women with COVID-19 would theoretically be those with min-549 imal fetal impact and/or minimal placental transfer. 550

The management of pregnant women with COVID-19 is essentially symptomatic. Therapies 551 must be discussed, based on rapidly evolving data on the efficacy and safety in non-pregnant 552 adults, also taking into account obstetric and fetal consequences of such treatment, but also 553 of the consequences of lack of therapy. In severe cases, therapy should not be withheld sole-554 ly because of pregnancy, and should be discussed between obstetricians, intensive care and 555 infectious diseases as well as the patient and her partner. 556 Table 1 : Transplacental drug transfer in humans and safety data in women and neonates exposed to medications used for the treatment of COVID-19 patients 

No specific data on transplacental transfer Sinclair (199) 

Déclaration sur la deuxième réunion du Comité d'urgence du Règlement sanitaire international

Coronavirus Disease 2019 (COVID-19) Pandemic and Pregnancy

Coronavirus Disease 2019 (COVID-19) and Pregnancy: What obstetricians need to know

Potential Maternal and Infant Outcomes from (Wuhan) Coronavirus 2019-nCoV Infecting Pregnant Women: Lessons from SARS, MERS, and Other Human Coronavirus Infections

Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States

Evidence and possible mechanisms of rare maternal-fetal transmission of SARS-CoV-2

Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records

An Analysis of 38 Pregnant Women with COVID-19, Their Newborn Infants, and Maternal-Fetal Transmission of SARS-CoV-2: Maternal Coronavirus Infections and Pregnancy Outcomes

Possible Vertical Transmission of SARS-CoV-2 From an Infected Mother to Her Newborn

Antibodies in Infants Born to Mothers With COVID-19 Pneumonia

Can SARS-CoV-2 Infection Be Acquired In Utero?: More Definitive Evidence Is Needed

Neonatal Early-Onset Infection With SARS-CoV-2 in 33 Neonates Born to Mothers With COVID-19 in Wuhan, China. JAMA Pediatr

Gynecol Obstet Fertil Senol

Clinical analysis of pregnant women with 2019 novel coronavirus pneumonia

Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review

Covid-19 , Démarrage de l'essai clinique Discovery

Public health emergency SOLIDARITY trial of treatments for COVID-19 infection in hospitalized patients

Association between prenatal exposure to antiretroviral therapy and birth defects: an analysis of the French perinatal cohort study (ANRS CO1/CO11)

Maternal and foetal outcomes among 4118 women with HIV infection treated with lopinavir/ritonavir during pregnancy: analysis of population-based surveillance data from the national study of HIV in pregnancy and childhood in the United Kingdom and Ireland

Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res

Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs

In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication [Internet]. Microbiology

Zika virus cell tropism in the developing human brain and inhibition by azithromycin

Azithromycin Inhibits the Replication of Zika Virus

Evaluation of Ebola Virus Inhibitors for Drug Repurposing

Chloroquine and its metabolites in human cord blood, neonatal blood, and urine after maternal medication

Transfer of chloroquine and desethylchloroquine across the placenta and into milk in Melanesian mothers

Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study

Ocular toxicity in children exposed in utero to antimalarial drugs: review of the literature

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

Combating COVID-19 with Chloroquine

Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial

Hydroxychloroquine in patients mainly with mild to moderate COVID-19: an open-label, randomized, controlled trial

No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection

Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19

No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial

Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease: A retrospective study

Hydroxychloroquine application is associated with a decreased mortality in critically ill patients with COVID-19

Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. The Lancet

Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France

JORF n°0012 du 15 janvier 2020. Texte n°13. Arrêté du 13 janvier 2020 portant classement sur les listes des substances vénéneuses.rtf

Hydroxychloroquine retinopathyimplications of research advances for rheumatology care

Hydroxychloroquine-induced Retinal Toxicity

Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature

Evidence of transplacental passage of hydroxychloroquine in humans

Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group

Disease-modifying antirheumatic drugs in pregnancy: current status and implications for the future

Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy

Electroretinograms of children born to mothers treated with hydroxychloroquine during pregnancy and breast-feeding: comment on the article by Costedoat-Chalumeau et al. Arthritis Rheum

A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

Prise en charge médicale des personnes vivants avec le VIH. Recommandations du groupe d'experts. Désir d'enfant et grossesse (mai 2018)

European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) Study Group. Nucleoside reverse transcriptase inhibitor backbones and pregnancy outcomes

Lopinavir/ritonavir monotherapy as a nucleoside analogue-sparing strategy to prevent HIV-1 mother-to-child transmission: the ANRS 135 PRIMEVA phase 2/3 randomized trial

Population approach to analyze the pharmacokinetics of free and total lopinavir in HIV-infected pregnant women and consequences for dose adjustment

Placental transfer of lopinavir/ritonavir in the ex vivo human cotyledon perfusion model

Transplacental transfer of antiretroviral drugs and newborn birth weight in HIV-infected pregnant women

Transplacental passage of protease inhibitors at delivery

Reduced indinavir exposure during pregnancy

Functional role of p-glycoprotein and binding protein effect on the placental transfer of lopinavir/ritonavir in the ex vivo human perfusion model

Placental transfer of darunavir in an ex vivo human cotyledon perfusion model

Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention

Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy

Association of prenatal and postnatal exposure to lopinavir-ritonavir and adrenal dysfunction among uninfected infants of HIV-infected mothers

Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir

Controlled Trial of Ebola Virus Disease Therapeutics

Broadspectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase

Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection

The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus

Remdesivir for the Treatment of Covid-19 -Preliminary Report

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet

Compassionate Use of Remdesivir for Patients with Severe Covid-19

Assessment report on Medicinal products under development for the treatment of Ebola

Avis relatif à la prise en charge des cas confirmés d'infection au virus SARS-CoV-2

Avis relatif à la prise en charge des cas confirmés d'infection au virus SARS-CoV-2

Epidemiology, Pathogenesis, and Control of COVID-19

Lack of Antiviral Activity of Darunavir against SARS-CoV-2 [Internet]. Infectious Diseases (except HIV/AIDS)

Transplacental transfer of oseltamivir phosphate and its metabolite oseltamivir carboxylate using the ex vivo human placenta perfusion model in Chinese Hans population

Oseltamivir use in pregnancy: Risk of birth defects, preterm delivery, and small for gestational age infants

Efficacy of favipiravir (T-705) in nonhuman primates infected with Ebola virus or Marburg virus

Favipiravir as a potential countermeasure against neglected and emerging RNA viruses

Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase

Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model

Laboratory Findings, Compassionate Use of Favipiravir, and Outcome in Patients With Ebola Virus Disease, Guinea, 2015-A Retrospective Observational Study

Combination Therapy with Oseltamivir and Favipiravir Delays Mortality but Does Not Prevent Oseltamivir Resistance in Immunodeficient Mice Infected with Pandemic A(H1N1) Influenza Virus. Viruses

Comparative effectiveness of combined favipiravir and oseltamivir therapy versus oseltamivir monotherapy in critically ill patients with influenza virus infection

Influenza virus polymerase inhibitors in clinical development

Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study

Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study

The Ribavirin Pregnancy Registry: Findings after 5 years of enrollment

Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost?

HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus

Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study

Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study

Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study

Pharmacokinetics of ivermectin after maternal or fetal intravenous administration in sheep

Safety of oral ivermectin during pregnancy: a systematic review and meta-analysis. Lancet Glob Health

Highlights of prescribing information, FDA.pdf

Final results from the Betaseron (interferon β-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events

Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry

Pregnancy outcomes from the global pharmacovigilance database on interferon beta-1b exposure

Experimental study of transplacental passage of alpha interferon by two assay techniques

Pharmacokinetics of interferon-alpha in pregnant women and fetoplacental passage

Pivotal Role of Convalescent Plasma in Managing Emerging Infectious Diseases. Vox Sang

Convalescent plasma: new evidence for an old therapeutic tool? Blood Transfus Trasfus Sangue

Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea

Use of convalescent plasma therapy in SARS patients in Hong Kong

Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection

Placental transport of immunoglobulin G. Vaccine

Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology

Placental transfer of tocilizumab in a patient with rheumatoid arthritis

Tocilizumab concentrations in maternal serum and breast milk during breastfeeding and a safety assessment in infants: a case study

Pregnancy outcomes after exposure to tocilizumab: A retrospective analysis of 61 patients in Japan

Tocilizumab use in pregnancy: Analysis of a global safety database including data from clinical trials and post-marketing data

The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation

International multi-centre study of pregnancy outcomes with interleukin-1 inhibitors. Rheumatol Oxf Engl

Benefit-Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis

Long-term efficacy and safety of fingolimod in Japanese patients with relapsing multiple sclerosis: 3-year results of the phase 2 extension study

Evaluation of pregnancy outcomes in patients with multiple sclerosis after fingolimod exposure

Baricitinib: A Review in Rheumatoid Arthritis

Baricitinib exposure during pregnancy in rheumatoid arthritis

The use of biologics and small molecules in pregnant patients with rheumatic diseases

Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease

Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn

Therapeutic infliximab drug level in a child born to a woman with ulcerative colitis treated until gestation week 31

Colchicine may not be effective in COVID-19 infection; it may even be harmful?

Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis

The Greek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): Rationale and study design

Transplacental passage of colchicine in familial Mediterranean fever

Use of colchicine in pregnancy: a systematic review and meta-analysis

Pregnancy outcome after in utero exposure to colchicine

The placental transfer of betamethasone

Drug therapy of the fetus

Placental 11 beta-hydroxysteroid dehydrogenase: barrier to maternal glucocorticoids

Prophylactic corticosteroids for preterm birth

Angiotensin II for the Treatment of COVID-19-Related Vasodilatory Shock

Angiotensin-converting enzyme 2: a functional receptor for SARS coronavirus

Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19

Angiotensin II receptor antagonist treatment during pregnancy

Renin Angiotensin System Blocker Fetopathy: A Midwest Pediatric Nephrology Consortium Report

Dysregulation of the placental renin-angiotensin system in human fetal growth restriction

Clinical effect of mifepristone on patients with ovarian cancer in pregnancy

Gynecologic cancer in pregnancy

Intravitreal Anti-VEGF Injections in Pregnancy: Case Series and Review of Literature

Intravitreal bevacizumab during pregnancy. Retina Phila Pa

A short history of thalidomide embryopathy

The saga of thalidomide. Neuropathy to embryopathy, with case reports of congenital anomalies

Multiple metastatic gestational trophoblastic disease after a twin pregnancy with complete hydatidiform mole and coexisting fetus, following assisted reproductive technology: Case report and literature review

Good pregnancy outcome after prenatal exposure to bleomycin, etoposide and cisplatin for ovarian immature teratoma: a case report and literature review

Methotrexate, bleomycin, and Etoposide in the treatment of gestational trophoblastic neoplasia

Requirement for etoposide in the treatment of pregnancy related hemophagocytic lymphohistiocytosis: a multicenter retrospective study

Liver Enzyme Elevation in Pregnant Women Receiving Antiretroviral Therapy in the ANRS-French Perinatal Cohort

Ethics of studies of drugs in pregnancy

Increasing the Participation of Pregnant Women in Clinical Trials

The ethics of excluding women who become pregnant while participating in clinical trials of anti-epileptic medications

The moral imperative to approve pregnant women's participation in randomized clinical trials for pregnancy and newborn complications

Models for Placental Transfer Studies of Drugs: Clin Pharmacokinet

Drug Transporters Expressed in the Human Placenta and Models for Studying Maternal-Fetal Drug Transfer

Placental transfer of elvitegravir and cobicistat in an ex-vivo human cotyledon double perfusion model

Contribution and limit of the model of perfused cotyledon to the study of placental transfer of drugs. Example of a protease inhibitor of HIV: nelfinavir

Prediction of human fetal pharmacokinetics using ex vivo human placenta perfusion studies and physiologically based models

Leflunomide use during pregnancy and the risk of adverse pregnancy outcomes

Oseltamivir in pregnancy and birth outcomes

The Ribavirin Pregnancy Registry: An Interim Analysis of Potential Teratogenicity at the Mid-Point of Enrollment

Sildenafil crosses the placenta at therapeutic levels in a dually perfused human cotyledon model

Sildenafil in Pregnancy: A Systematic Review of Maternal Tolerance and Obstetric and Perinatal Outcomes

Antenatal sildenafil administration to prevent pulmonary hypertension in congenital diaphragmatic hernia (SToP-PH): study protocol for a phase I/IIb placenta transfer and safety study

The effects of sildenafil in maternal and fetal outcomes in pregnancy: A systematic review and meta-analysis